Aripiprazole Tablet
Product Images NDC 16714-142

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 16714-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg3oscount (10mg3oscount)

Aripiprazole Tablets, USP 10 mg oral tablets packaging label by NorthStar Rx LLC. The label states the package contains 30 tablets with each tablet containing 10 mg of Aripiprazole. It includes storage instructions, manufacturer details, a barcode, and notes for pharmacists to dispense a Medication Guide.*

FDA Label Image

15mg3oscount (15mg3oscount)

Aripiprazole Tablets, USP 15 mg oral tablets, packaged with 30 tablets per container. The label includes manufacturer NorthStar Rx LLC and states the product is manufactured by Hetero Labs Limited, India. It provides NDC 16714-144-01 and dosing/storage information.*

FDA Label Image

20mg3oscount (20mg3oscount)

Label for Aripiprazole Tablets, USP 20 mg oral tablets by NorthStar Rx LLC. The package contains 30 tablets. The label includes dosage instructions, storage conditions (20° to 25°C), and manufacturer details indicating Hetero Labs Limited, India. A barcode and batch coding area are shown.*

FDA Label Image

2mg3oscount (2mg3oscount)

Label for Aripiprazole Tablets USP, 2 mg, oral tablets supplied by NorthStar Rx LLC. The package contains 30 tablets. The label includes dosage information, storage instructions, medication guide contact details, and manufacturing information indicating production by Hetero Labs Limited, India.*

FDA Label Image

30mg3oscount (30mg3oscount)

Box label for Aripiprazole Tablets, USP 30 mg oral tablets. The package contains 30 tablets and is labeled for prescription use only (Rx only). The label includes dosing instructions, storage conditions, a barcode, and manufacturing information identifying NorthStar Rx LLC, Memphis, TN, and Hetero Labs Limited in India as the manufacturer.*

FDA Label Image

5mg3oscount (5mg3oscount)

Aripiprazole Tablets, USP 5 mg oral tablets in a blister card packaging. Contains 30 tablets labeled for prescription use only (Rx only). The label shows the manufacturer as NorthStar Rx LLC and indicates the product is made in India by Hetero Labs Limited. Instructions include dosage information, storage conditions, and a medication guide reference.*

FDA Label Image

Figure1 (Figure1)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for Aripiprazole's pharmacokinetics (AUC and Cmax) when coadministered with various drugs. The x-axis represents change relative to reference without interacting drug, ranging approximately from 0 to 3. The y-axis lists drug interactions grouped by type: CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). Data points include fold changes with confidence intervals for AUC and Cmax values.*

FDA Label Image

Figure2 (Figure2)

A pharmacokinetic chart showing the effect of various drugs on Aripiprazole's metabolite levels, represented as fold change and 90% confidence intervals. The x-axis indicates change relative to a reference without interacting drugs, ranging from 0.0 to 3.0. The y-axis lists inhibitors, inducers, and other drug types affecting AUC and Cmax values.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for pharmacokinetic parameters such as DMDRP, AUC, Cmax, and INR across various drugs metabolized by enzymes CYP2D6, CYP2C9, 2C19, UGT1A4, and others. The x-axis represents fold change relative to reference without interacting drug, ranging from 0.5 to 3.0, with data points clustered mainly around 1.0 indicating minimal effect.*

FDA Label Image

Figure4 (Figure4)

A chart titled 'Aripiprazole Fold Change and 90% CI,' showing fold changes in pharmacokinetic parameters AUC and Cmax across special populations including CYP2D6 metabolizer status, gender, age, hepatic and renal impairment. The horizontal axis depicts change relative to reference values, ranging from 0.5 to 3.0, with data points and confidence intervals indicating variability in these subgroups.*

FDA Label Image

Figure5 (Figure5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the fold changes in AUC and Cmax for various factors including CYP2D6 metabolism, gender, age, hepatic impairment, and severe renal impairment compared to reference values. The x-axis represents change relative to reference, ranging from 0 to over 3, and the y-axis lists the factors with multiple data points indicating fold change values with confidence intervals.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of aripiprazole, showing the molecular arrangement including chlorophenyl, piperazine, and quinolinone moieties consistent with the active ingredient aripiprazole.*

FDA Label Image

Figure 6 (Figure 6)

A Kaplan-Meier curve comparing the proportion of subjects with relapse over days from randomization for Aripiprazole versus placebo. The chart shows time on the horizontal axis (0 to 182 days) and proportion with relapse on the vertical axis (0.0 to 1.0). The graph includes a table of number of subjects at risk for each group below the time axis.*

FDA Label Image

Figure 7 (Figure 7)

A Kaplan-Meier survival curve showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole and placebo groups. The graph includes lines for Aripiprazole (solid) and placebo (dashed), along with the number of subjects at risk at various time points.*

FDA Label Image

Figure 8 (Figure 8)

A line graph depicting the proportion of subjects with relapse over days from randomization comparing Aripiprazole and placebo groups. The x-axis shows days from randomization ranging up to 364, and the y-axis represents the proportion with relapse. The graph includes a table indicating the number of subjects at risk for each group at various time points. Aripiprazole shows a lower relapse proportion compared to placebo throughout the period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.